NEW YORK, Feb. 15, 2023 /PRNewswire/ -- The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Source: ReportLinker Research
Read the full report: https://www.reportlinker.com/p06051228/?utm_source=PRN
In the changed post COVID-19 business landscape, the global market for Melanoma TherapeuticsMelanoma Therapeutics estimated at US$3.3 Billion in the year 2022, is projected to reach a revised size of US$9.5 Billion by 2030, growing at a CAGR of 13.9% over the analysis period 2022-2030. Cutaneous Melanoma, one of the segments analyzed in the report, is projected to record a 14% CAGR and reach US$4.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Ocular Melanoma segment is readjusted to a revised 14.9% CAGR for the next 8-year period. The U.S. Market is Estimated at $911.9 Million, While China is Forecast to Grow at 18.8% CAGR
The Melanoma TherapeuticsMelanoma Therapeutics market in the U.S. is estimated at US$911.9 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 18.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.3% and 11.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 11% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.5 Billion by the year 2030. Select Competitors (Total 14 Featured)
Read the full report: https://www.reportlinker.com/p06051228/?utm_source=PRN
Influencer Market Insights
World Market Trajectories
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession Cancer Evolves Into the Global Epidemic
Global New Cancer Incidence (In Million) for the Year 2020
COVID-19 Extends a Major Setback to the World?s Battle Against Melanoma: Disease Causes, Risks, Types, Symptoms, Diagnosis & Global Skin Cancer Cases (Per 100,000 People) by Country for 2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Depletion of Ozone Layer & Increase in Ground-Level Ultraviolet
Radiation: A Key Reason for Rising Incidence of Melanoma Melanoma Mortality in the U.S. for the Years 2015, 2017, 2019, New Melanoma Cancer Cases in the U.S. for the Year 2021
Targeted Therapies Grow in Popularity for Treating Melanoma Advancements in the Field of Genomics Brings Hope for the
Development of More Potent Cancer Drugs
What Are the Approved Drugs for Melanoma? Artificial Intelligence Helps Speed Up & Automate Melanoma Global Market for AI in Healthcare (US$ Billion) for Years
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for Melanoma TherapeuticsMelanoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR Table 2: World Historic Review for Melanoma TherapeuticsMelanoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 3: World 18-Year Perspective for Melanoma TherapeuticsMelanoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030 Table 4: World Recent Past, Current & Future Analysis for Cutaneous Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR Table 5: World Historic Review for Cutaneous Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 6: World 18-Year Perspective for Cutaneous Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030 Table 7: World Recent Past, Current & Future Analysis for Ocular Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR Table 8: World Historic Review for Ocular Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 9: World 18-Year Perspective for Ocular Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030 Table 10: World Recent Past, Current & Future Analysis for Mucosal Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR Table 11: World Historic Review for Mucosal Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 12: World 18-Year Perspective for Mucosal Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030 Table 13: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 14: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
Table 15: World 18-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
Table 16: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 17: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
Table 18: World 18-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
Table 19: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 20: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
Table 21: World 18-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
Table 22: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 23: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
Table 24: World 18-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
Table 25: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 26: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
Table 27: World 18-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
Table 28: World Melanoma Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030 Table 32: USA Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR Table 33: USA Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 34: USA 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030 Table 38: Canada Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR Table 39: Canada Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 40: Canada 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030 Table 44: Japan Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR Table 45: Japan Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 46: Japan 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030 Table 50: China Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR Table 51: China Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 52: China 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030 Table 53: Europe Recent Past, Current & Future Analysis for Melanoma TherapeuticsMelanoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR Table 54: Europe Historic Review for Melanoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 55: Europe 18-Year Perspective for Melanoma TherapeuticsMelanoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030 Table 59: Europe Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR Table 60: Europe Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 61: Europe 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030 Table 65: France Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR Table 66: France Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 67: France 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030 Table 71: Germany Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR Table 72: Germany Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 73: Germany 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030 Table 77: Italy Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR Table 78: Italy Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 79: Italy 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030 Table 83: UK Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR Table 84: UK Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 85: UK 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030 Table 89: Spain Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR Table 90: Spain Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 91: Spain 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030 Table 95: Russia Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR Table 96: Russia Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 97: Russia 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030 Table 101: Rest of Europe Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR Table 102: Rest of Europe Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 103: Rest of Europe 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030 Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Melanoma TherapeuticsMelanoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR Table 105: Asia-Pacific Historic Review for Melanoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 106: Asia-Pacific 18-Year Perspective for Melanoma TherapeuticsMelanoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030 Table 110: Asia-Pacific Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR Table 111: Asia-Pacific Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 112: Asia-Pacific 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030 Table 116: Australia Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR Table 117: Australia Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR Table 118: Australia 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030 Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06051228/?utm_source=PRN
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: [email protected]